News | October 23, 2022
Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
Subscribe To Our Newsletter & Stay Updated
